Announcements
- Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
- Rhythm Pharmaceuticals Announces New Employment Inducement Grants
- Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
- Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
- Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
- Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
- Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
- Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
- Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
- Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
More ▼
Key statistics
On Wednesday, Rhythm Pharmaceuticals Inc (RYTM:MEX) closed at 680.21, -7.26% below its 52-week high of 733.48, set on Jan 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | 740.00 |
Previous close | 680.21 |
Average volume | -- |
---|---|
Shares outstanding | 60.97m |
Free float | 57.38m |
P/E (TTM) | -- |
Market cap | 2.21bn USD |
EPS (TTM) | -4.62 USD |
Data delayed at least 20 minutes, as of Apr 24 2024 12:30 BST.
More ▼